tiprankstipranks
CVS Health Corp (DE:CVS)
NYSE:CVS
Germany Market
CVS
CVS Health
RESEARCH TOOLSreports

CVS Health (CVS) Stock Forecast & Price Target

33 Followers
See the Price Targets and Ratings of:

CVS Analyst Ratings

Strong Buy
18Ratings
Strong Buy
18 Buy
0 Hold
0 Sell
Based on 18 analysts giving stock ratings to
CVS
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CVS Stock 12 Month Forecast

Average Price Target

€90.58
▲(38.80% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for CVS Health in the last 3 months. The average price target is €90.58 with a high forecast of €99.66 and a low forecast of €79.72. The average price target represents a 38.80% change from the last price of €65.26.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"51":"€51","100":"€100","63.25":"€63.3","75.5":"€75.5","87.75":"€87.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":99.6555385,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€99.66</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":90.58204190000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€90.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":79.7244308,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€79.72</span>\n  </div></div>","useHTML":true}}],"tickPositions":[51,63.25,75.5,87.75,100],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.86,79.53657988461538,81.21315976923077,82.88973965384615,84.56631953846154,86.24289942307692,87.91947930769231,89.59605919230769,91.27263907692308,92.94921896153846,94.62579884615386,96.30237873076923,97.97895861538461,{"y":99.6555385,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.86,78.83861860769231,79.81723721538462,80.79585582307692,81.77447443076923,82.75309303846154,83.73171164615385,84.71033025384615,85.68894886153846,86.66756746923078,87.64618607692309,88.62480468461538,89.6034232923077,{"y":90.58204190000001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.86,78.00341775384615,78.1468355076923,78.29025326153845,78.43367101538462,78.57708876923077,78.72050652307692,78.86392427692307,79.00734203076922,79.15075978461537,79.29417753846154,79.43759529230769,79.58101304615384,{"y":79.7244308,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.242,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.162,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.087,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.16,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.529,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.27,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.955,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.674,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.127,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.951,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.96,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.86,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€99.66Average Price Target€90.58Lowest Price Target€79.72
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on DE:CVS
Lance Wilkes
Bernstein
Bernstein
€91.86
Buy
40.75%
Upside
Reiterated
06/09/26
Bernstein Remains a Buy on CVS Health (CVS)
Mizuho Securities Analyst forecast on DE:CVS
Ann Hynes
Mizuho Securities
Mizuho Securities
€95.32→€99.66
Buy
52.71%
Upside
Reiterated
06/08/26
CVS Health price target raised to $115 from $110 at MizuhoCVS Health price target raised to $115 from $110 at Mizuho
UBS Analyst forecast on DE:CVS
Kevin Caliendo
UBS
UBS
€86.66→€99.66
Buy
52.71%
Upside
Reiterated
06/08/26
Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (NASDAQ: SENS) and CVS Health (NYSE: CVS)
Morgan Stanley Analyst forecast on DE:CVS
Erin Wright
Morgan Stanley
Morgan Stanley
€91.86→€96.19
Buy
47.39%
Upside
Assigned
06/04/26
CVS Health price target raised to $111 from $106 at Morgan StanleyCVS Health price target raised to $111 from $106 at Morgan Stanley
Wells Fargo Analyst forecast on DE:CVS
Stephen Baxter
Wells Fargo
Wells Fargo
€89.26
Buy
36.77%
Upside
Reiterated
06/04/26
Analysts Offer Insights on Healthcare Companies: CVS Health (NYSE: CVS), TG Therapeutics (NASDAQ: TGTX) and Dexcom (NASDAQ: DXCM)
Truist Financial Analyst forecast on DE:CVS
David S Macdonald
Truist Financial
Truist Financial
€88.39→€93.59
Buy
43.41%
Upside
Reiterated
06/01/26
CVS Health price target raised to $108 from $102 at TruistCVS Health price target raised to $108 from $102 at Truist
J.P. Morgan Analyst forecast on DE:CVS
Lisa Gill
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
05/27/26
Analysts Offer Insights on Healthcare Companies: CVS Health (NYSE: CVS), Dexcom (NASDAQ: DXCM) and HCA Healthcare (NYSE: HCA)
Barclays Analyst forecast on DE:CVS
Andrew Mok CFA
Barclays
Barclays
€87.52→€91.86
Buy
40.75%
Upside
Reiterated
05/26/26
CVS Health price target raised to $106 from $101 at BarclaysCVS Health price target raised to $106 from $101 at Barclays
Argus Research Analyst forecast on DE:CVS
Steven Silver
Argus Research
Argus Research
€77.99→€90.12
Buy
38.10%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: CVS Health (NYSE: CVS), BioMarin Pharmaceutical (NASDAQ: BMRN) and AbbVie (NYSE: ABBV)
TD Cowen Analyst forecast on DE:CVS
Charles Rhyee
TD Cowen
TD Cowen
€90.99→€95.32
Buy
46.07%
Upside
Reiterated
05/11/26
Analysts Conflicted on These Healthcare Names: Agilon Health (NYSE: AGL) and CVS Health (NYSE: CVS)
Bank of America Securities Analyst forecast on DE:CVS
Allen Lutz
Bank of America Securities
Bank of America Securities
€86.66
Buy
32.79%
Upside
Reiterated
05/07/26
Analysts Are Bullish on Top Healthcare Stocks: CVS Health (CVS), Mineralys Therapeutics, Inc. (MLYS)
Deutsche Bank Analyst forecast on DE:CVS
George Hill
Deutsche Bank
Deutsche Bank
€76.26→€79.72
Buy
22.16%
Upside
Reiterated
05/07/26
CVS Health price target raised to $92 from $88 at Deutsche BankCVS Health price target raised to $92 from $88 at Deutsche Bank
Goldman Sachs Analyst forecast on DE:CVS
Scott Fidel
Goldman Sachs
Goldman Sachs
€84.06→€90.12
Buy
38.10%
Upside
Reiterated
05/07/26
CVS Health (CVS) Receives a Buy from Goldman Sachs
Evercore ISI Analyst forecast on DE:CVS
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
€86.66→€90.99
Buy
39.43%
Upside
Reiterated
05/07/26
CVS Health price target raised to $105 from $100 at Evercore ISICVS Health price target raised to $105 from $100 at Evercore ISI
RBC Capital Analyst forecast on DE:CVS
Ben Hendrix
RBC Capital
RBC Capital
€80.59→€92.72
Buy
42.08%
Upside
Reiterated
05/06/26
RBC Capital Sticks to Their Buy Rating for CVS Health (CVS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on DE:CVS
Lance Wilkes
Bernstein
Bernstein
€91.86
Buy
40.75%
Upside
Reiterated
06/09/26
Bernstein Remains a Buy on CVS Health (CVS)
Mizuho Securities Analyst forecast on DE:CVS
Ann Hynes
Mizuho Securities
Mizuho Securities
€95.32→€99.66
Buy
52.71%
Upside
Reiterated
06/08/26
CVS Health price target raised to $115 from $110 at MizuhoCVS Health price target raised to $115 from $110 at Mizuho
UBS Analyst forecast on DE:CVS
Kevin Caliendo
UBS
UBS
€86.66→€99.66
Buy
52.71%
Upside
Reiterated
06/08/26
Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (NASDAQ: SENS) and CVS Health (NYSE: CVS)
Morgan Stanley Analyst forecast on DE:CVS
Erin Wright
Morgan Stanley
Morgan Stanley
€91.86→€96.19
Buy
47.39%
Upside
Assigned
06/04/26
CVS Health price target raised to $111 from $106 at Morgan StanleyCVS Health price target raised to $111 from $106 at Morgan Stanley
Wells Fargo Analyst forecast on DE:CVS
Stephen Baxter
Wells Fargo
Wells Fargo
€89.26
Buy
36.77%
Upside
Reiterated
06/04/26
Analysts Offer Insights on Healthcare Companies: CVS Health (NYSE: CVS), TG Therapeutics (NASDAQ: TGTX) and Dexcom (NASDAQ: DXCM)
Truist Financial Analyst forecast on DE:CVS
David S Macdonald
Truist Financial
Truist Financial
€88.39→€93.59
Buy
43.41%
Upside
Reiterated
06/01/26
CVS Health price target raised to $108 from $102 at TruistCVS Health price target raised to $108 from $102 at Truist
J.P. Morgan Analyst forecast on DE:CVS
Lisa Gill
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
05/27/26
Analysts Offer Insights on Healthcare Companies: CVS Health (NYSE: CVS), Dexcom (NASDAQ: DXCM) and HCA Healthcare (NYSE: HCA)
Barclays Analyst forecast on DE:CVS
Andrew Mok CFA
Barclays
Barclays
€87.52→€91.86
Buy
40.75%
Upside
Reiterated
05/26/26
CVS Health price target raised to $106 from $101 at BarclaysCVS Health price target raised to $106 from $101 at Barclays
Argus Research Analyst forecast on DE:CVS
Steven Silver
Argus Research
Argus Research
€77.99→€90.12
Buy
38.10%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: CVS Health (NYSE: CVS), BioMarin Pharmaceutical (NASDAQ: BMRN) and AbbVie (NYSE: ABBV)
TD Cowen Analyst forecast on DE:CVS
Charles Rhyee
TD Cowen
TD Cowen
€90.99→€95.32
Buy
46.07%
Upside
Reiterated
05/11/26
Analysts Conflicted on These Healthcare Names: Agilon Health (NYSE: AGL) and CVS Health (NYSE: CVS)
Bank of America Securities Analyst forecast on DE:CVS
Allen Lutz
Bank of America Securities
Bank of America Securities
€86.66
Buy
32.79%
Upside
Reiterated
05/07/26
Analysts Are Bullish on Top Healthcare Stocks: CVS Health (CVS), Mineralys Therapeutics, Inc. (MLYS)
Deutsche Bank Analyst forecast on DE:CVS
George Hill
Deutsche Bank
Deutsche Bank
€76.26→€79.72
Buy
22.16%
Upside
Reiterated
05/07/26
CVS Health price target raised to $92 from $88 at Deutsche BankCVS Health price target raised to $92 from $88 at Deutsche Bank
Goldman Sachs Analyst forecast on DE:CVS
Scott Fidel
Goldman Sachs
Goldman Sachs
€84.06→€90.12
Buy
38.10%
Upside
Reiterated
05/07/26
CVS Health (CVS) Receives a Buy from Goldman Sachs
Evercore ISI Analyst forecast on DE:CVS
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
€86.66→€90.99
Buy
39.43%
Upside
Reiterated
05/07/26
CVS Health price target raised to $105 from $100 at Evercore ISICVS Health price target raised to $105 from $100 at Evercore ISI
RBC Capital Analyst forecast on DE:CVS
Ben Hendrix
RBC Capital
RBC Capital
€80.59→€92.72
Buy
42.08%
Upside
Reiterated
05/06/26
RBC Capital Sticks to Their Buy Rating for CVS Health (CVS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CVS Health

3 Months
Elizabeth Anderson CFAEvercore ISI
Success Rate
16/24 ratings generated profit
67%
Average Return
+6.95%
Copying Elizabeth Anderson CFA's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +6.95% per trade.
1 Year
Allen LutzBank of America Securities
Success Rate
18/24 ratings generated profit
75%
Average Return
+21.57%
Copying Allen Lutz's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +21.57% per trade.
2 Years
Allen LutzBank of America Securities
Success Rate
24/24 ratings generated profit
100%
Average Return
+44.99%
Copying Allen Lutz's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +44.99% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CVS Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
34
21
22
34
38
Hold
7
5
1
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
41
26
23
34
38
In the current month, CVS has received 38 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CVS average Analyst price target in the past 3 months is 90.58.
Each month's total comprises the sum of three months' worth of ratings.

CVS Financial Forecast

CVS Earnings Forecast

Next quarter’s earnings estimate for CVS is €1.59 with a range of €1.28 to €1.79. The previous quarter’s EPS was €2.23. CVS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CVS has Performed in-line its overall industry.
Next quarter’s earnings estimate for CVS is €1.59 with a range of €1.28 to €1.79. The previous quarter’s EPS was €2.23. CVS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CVS has Performed in-line its overall industry.

CVS Sales Forecast

Next quarter’s sales forecast for CVS is €86.91B with a range of €84.51B to €91.07B. The previous quarter’s sales results were €87.14B. CVS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CVS has Performed in-line its overall industry.
Next quarter’s sales forecast for CVS is €86.91B with a range of €84.51B to €91.07B. The previous quarter’s sales results were €87.14B. CVS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CVS has Performed in-line its overall industry.

CVS Stock Forecast FAQ

What is DE:CVS’s average 12-month price target, according to analysts?
Based on analyst ratings, CVS Health Corp’s 12-month average price target is 90.58.
    What is DE:CVS’s upside potential, based on the analysts’ average price target?
    CVS Health Corp has 38.80% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CVS Health Corp a Buy, Sell or Hold?
          CVS Health Corp has a consensus rating of Strong Buy, which is based on 18 buy ratings, 0 hold ratings and 0 sell ratings.
            What is CVS Health Corp’s share price target?
            The average share price target for CVS Health Corp is 90.58. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €99.66 ,and the lowest forecast is €79.72. The average share price target represents 38.80% Increase from the current price of €65.26.
              What do analysts say about CVS Health Corp?
              CVS Health Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of CVS Health Corp?
                To buy shares of DE:CVS, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.